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OBJECTIVES We sought to report the first and repeat events and to separate spontaneous and procedure-
related events over two years in the Fast Revascularization during InStability in Coronary
artery disease (FRISC-II) invasive trial.
BACKGROUND The FRISC-II invasive trial compared the long-term effects of an early invasive versus
noninvasive strategy, in terms of death and myocardial infarction (MI) and the need for repeat
hospital admissions and late revascularization procedures in patients with coronary artery
disease (UCAD).
METHODS In the FRISC-II trial, 2,457 patients with UCAD were randomized to an early invasive or
noninvasive strategy.
RESULTS At 24 month follow-up, there were reductions in mortality (n 45 [3.7%] vs. 67 [5.4%]; risk
ratio 0.68 [95% confidence interval (CI) 0.47 to 0.98]; p  0.038), MI (n  111 [9.2%] vs.
156 [12.7%]; risk ratio 0.72 [95% CI 0.57 to 0.91]; p  0.005), and the composite end point
of death or MI (n  146 [12.1%] vs. 200 [16.3%]; risk ratio 0.74 [95% CI 0.61 to 0.90]; p
 0.003) in the invasive compared with the noninvasive group. Procedure-related MIs were
two to three times more common, but spontaneous ones were three times less common in the
invasive than in the noninvasive group. After the first year, there was no difference in
mortality (n  20 [1.7%]) between the two groups and fewer MIs in the invasive group (p 
0.031).
CONCLUSIONS In UCAD, the early invasive approach leads to a sustained reduction in mortality, cardiac
morbidity, and the need for repeat hospital admissions and late revascularization procedures.
Although the benefits are greatest during the first months, during the second year, cardiac
morbidity is lower and the need for hospital care is less in the invasive group. (J Am Coll
Cardiol 2002;40:1902–14) © 2002 by the American College of Cardiology Foundation
An early invasive strategy using coronary angiography and,
if appropriate, revascularization has recently become the
recommended treatment for the majority of patients with
unstable coronary artery disease (UCAD) in the Western
countries (1). Evidence for the superiority, with respect to
See page 1915
event-free survival, of an invasive treatment over a more
conservative approach has been lacking for a long time. In
the early Veterans Affairs study of unstable angina, compar-
ing coronary artery bypass graft surgery (CABG) with
medical treatment, there was no survival benefit, except in
patients with poor left ventricular function (2,3). In the
Veterans Affairs Non–Q-Wave Infarction Strategies in
Hospital (VANQWISH) trial including men with non–Q-
wave myocardial infarction (MI), the early invasive strategy
was associated with higher early mortality, which was
sustained for more than a year (4). The Thrombolysis In
Myocardial Infarction (TIMI-IIIB) trial of non–ST-
segment elevation acute coronary syndrome reported shorter
hospital stays and less need for anti-anginal medication, but
no difference in cardiac events by using an early invasive
approach (5).
The Fast Revascularization during InStability in Coro-
nary artery disease (FRISC-II) trial was the first random-
ized study to convincingly demonstrate a better outcome in
patients treated with an early invasive strategy, with a
reduction in the primary composite end point of death/MI
after six months (6). At 12-month follow-up, there were
significant reductions in both mortality and MI alone (7).
These results were supported by the recently reported
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TACTICS–TIMI-18 trial, which showed a lower rate of
MI and composite events in the early invasive cohort after
six months (8).
This report presents a two-year perspective on the effects
of an invasive strategy on mortality, MI, early and late
revascularization, and repeat hospital admission in the
FRISC-II trial. The analysis also includes data on
procedure-related and spontaneous MIs and repeat events
in the same patients.
METHODS
Study design. The objective of the invasive part of the
FRISC-II trial was to compare an early invasive with an
early noninvasive strategy in patients with UCAD with a
primary composite end point of death or MI at six months.
Other predefined end points were death, MI, late revascu-
larizations, and repeat admissions to the hospital, as well as
cardiac symptoms at 6, 12, and 24 months. The results at 6
and 12 months have already been published (6,7). The
FRISC-II study was a prospective, randomized, multicenter
trial with parallel groups. The invasive versus noninvasive
comparison was carried out in a factorial design. Half of the
patients within each group were also randomized to contin-
ued treatment with subcutaneous dalteparin or placebo for
three months.
Patients, medications, and procedures. Between June 17,
1996 and August 28, 1998, 2,457 patients were included
and randomized to the invasive or noninvasive arm of
FRISC-II in 58 Scandinavian hospitals. The detailed inclu-
sion criteria, exclusion criteria, study design, and results up
to 12 months have previously been published (6,7). In short,
patients were eligible if they were admitted with symptoms
of UCAD with the last episode of chest pain within 48 h
before the start of treatment with low-molecular-weight
heparin (dalteparin) or regular heparin and if they had
demonstrated signs of myocardial ischemia (i.e., ST-
segment depression, T-wave inversion, raised biochemical
myocardial markers). Excluded were patients with an indi-
cation for thrombolysis or those treated with thrombolysis
within the past 24 hours, angioplasty within the last six
months, previous open-heart surgery, advanced age (e.g.,
75 years), or other conditions that made randomization to
early revascularization inappropriate. All patients received
aspirin and open-label dalteparin for at least five days; in the
invasive group, they always received it until the evening
before revascularization. Beta-blockers were given unless
contraindicated. Statins and angiotensin-converting enzyme
inhibitors were recommended according to modern treat-
ment guidelines.
In the invasive strategy, the aim was to perform coronary
angiography and, if appropriate, revascularization within
seven days of hospital admission. Revascularization was
recommended in all patients with 70% diameter stenosis
in any artery supplying a significant proportion of the
myocardium. Percutaneous coronary intervention (PCI) was
recommended in one or two significant lesions, whereas
CABG was the preferred treatment in patients with three-
vessel or left main coronary artery disease. The noninvasive
strategy recommended coronary angiography in patients
with refractory or recurrent symptoms, despite maximal
medical treatment or severe ischemia on a predischarge
symptom-limited exercise test. During long-term follow-
up, invasive procedures should be considered, regardless of
the randomized strategy, for all patients with incapacitating
symptoms, recurrence of instability, or MI.
Events. The patients’ outcome events while in the hospital
were evaluated by telephone contact after two weeks, by
outpatient visits after six weeks, three months, and 6
months, and by telephone contact after 12 and 24 months.
The vital status of patients lost to follow-up was collected in
hospital records and national population registries. During
the first six months, all reported deaths, MIs, elevation of
biochemical markers in relation to PCI procedures, and new
Q waves reported by the electrocardiography core laboratory
were adjudicated by an independent Clinical Events Com-
mittee. After the first six months, information on further
Table 1. Mortality During Two Years in Six-Month Periods in the Invasive and
Noninvasive Groups
n*
Invasive
Group
Noninvasive
Group
Risk
Ratio 95% CI p Value
First week† 1,222/1,235 5 (0.4%) 4 (0.3%) 1.26 0.34–4.69
Second week to 6 months 1,217/1,231 18 (1.5%) 32 (2.6%) 0.57 0.32–1.01
7 to 12 months 1,199/1,199 4 (0.3%) 12 (1.0%) 0.33 0.11–1.03
13 to 18 months 1,195/1,187 11 (0.9%) 9 (0.8%) 1.21 0.50–2.92
19 to 24 months 1,184/1,178 7 (0.6%) 10 (0.8%) 0.70 0.27–1.82
Total 0 to 24 months 1,222/1,235 45 (3.7%) 67 (5.4%) 0.68 0.47–0.98 0.038
*Figures show evaluated patients in the invasive/noninvasive groups. †The first six-month period is subdivided into the first week
and second week to six months.
CI  confidence interval.
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CI  confidence interval
FRISC-II  Fast Revascularization during InStability in
Coronary artery disease trial
MI  myocardial infarction
PCI  percutaneous coronary intervention
UCAD  unstable coronary artery disease
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Figure 1. Probability of death (A), myocardial infarction (B), and death or myocardial infarction (C) in the invasive (n  1,222, continuous broad line)
and noninvasive (n  1,235, dotted narrow line) groups, illustrated by Kaplan-Meier (1  survival) curves. Continued on next page.
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events was based on investigator report forms, outpatient
visits, or telephone contact with all surviving patients. In
case of repeat admission to the hospital, the diagnosis was
obtained from the hospital records. The reasons for death
after six months were either based on hospital records or
death certificates. During the first six months, the Clinical
Events Committee classified the MIs as “spontaneous” or
“procedure-related.” Thereafter, all MIs occurring on the
day of or the day after a coronary procedure were considered
“procedure-related”, and the others, accordingly, as “spon-
taneous.”
Statistics and data management. All statistical analyses
were performed on an intention-to-treat basis. The efficacy
analyses were based on events occurring from the start of
open-label dalteparin treatment until 24 months. The effi-
cacy analyses were point estimates including only patients
with an adjudicated event or with a recorded absence of the
evaluated event until at least 670 days of follow-up. The
differences between the groups were evaluated for the whole
period of follow-up and for shorter intervals (i.e., initial 7
days, 2nd week to 6 months, 7 to 12 months, 13 to 18
months, and 19 to 24 months). The chi-squared test was
used to test the significance of the degree of association
between dichotomous variables, if not otherwise stated. The
results are presented as the risk ratio with 95% confidence
interval (CI). The Kaplan-Meier estimate of survival func-
tion was used, and differences between survival curves were
estimated by the log-rank test. Data processing and statis-
Table 2. Patients With Myocardial Infarctions During Two Years in Six-Month Periods in the
Invasive and Noninvasive Groups
n*
Invasive
Group
Noninvasive
Group
Risk
Ratio 95% CI p Value
First week† 1,222/1,235 63 (5.2%) 32 (2.6%) 1.99 1.31–3.02
Second week to 6 months 1,213/1,223 32 (2.6%) 93 (7.6%) 0.35 0.23–0.51
7 to 12 months 1,192/1,193 13 (1.1%) 18 (1.5%) 0.72 0.36–1.47
13 to 18 months 1,185/1,180 7 (0.6%) 11 (0.9%) 0.63 0.25–1.62
19 to 24 months 1,171/1,169 5 (0.4%) 9 (0.8%) 0.56 0.19–1.65
Total 0 to 24 months 1,210/1,227 111 (9.2%) 156 (12.7%) 0.72 0.57–0.91 0.005
*Figures show evaluated patients in the invasive/noninvasive groups. †The first six-month period is subdivided into the first week
and second week to six months.
CI  confidence interval.
Figure 1 Continued.
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Figure 2. Probability of death (A), myocardial infarction (B), and death or myocardial infarction (C) in the invasive (continuous broad line) and
noninvasive (dotted narrow line) groups in the period from 12 months until the last follow-up contact, illustrated by Kaplan-Meier (1  survival) curves.
The p value was derived by the log-rank test between the two groups. Continued on next page.
tical analyses were performed by the coordinating center,
using the SPSS version 10.0 statistical program on a
personal computer. The study complied with the Declara-
tion of Helsinki, and all local Ethics Committees approved
the protocol.
RESULTS
In May 2001, the vital status was known for all 2,457
patients up to 670 days after randomization. Complete
information on other events was lacking in 22 patients
(0.9%)—13 in the invasive and 9 in the noninvasive group—
mainly because of requests from or the inability to track
these patients.
The 24-month follow-up contact usually occurred later
than planned; the median time was 749 days (735 to 773
days for 25th to 75th percentile). As previously reported (6),
there were no significant differences in the baseline charac-
teristics between the randomized groups. In short, the
median age was 65 years; 70% were men; 30% were treated
for hypertension; 12% had diabetes; and 23% had experi-
enced a previous MI.
Mortality. In the first week, there were few deaths in either
group (Table 1). During the remainder of the first six
months, there were 18 deaths in the invasive group and 32
deaths in the noninvasive group. Also, from 6 to 12 months,
there were fewer deaths in the invasive group, with a
12-month mortality rate of 2.2% in the invasive group
compared with 3.9% in the noninvasive group. This abso-
lute difference of 1.7% was maintained throughout the
second year (Fig. 1A). During the second year, 18 patients
died in the invasive group and 19 in the noninvasive
group. Therefore, at 24 months, there were still less
deaths in the invasive group (n  45 [3.7%]) than in the
noninvasive group (n  67 [5.4%], p  0.038) (Table 2
and Fig. 1A). Of the 75 patients who died during the first
12 months, 56 (75%) died suddenly or from known
cardiac reasons or stroke: 19 in the invasive group and 37
in the noninvasive group. During the second year, the
cause of death was sudden death, known cardiac reasons,
Table 3. Number of Spontaneous and Procedure-Related MIs*
During the First Six Months in the Invasive and Noninvasive
Groups
Invasive
Group (n)
Noninvasive
Group (n)
Procedure-related MIs 66 26
CABG-related 13 8
PCI-related 51 13
Angiography-related 2 5
Spontaneous MIs 36 113
*Classified as procedure-related or spontaneous by the independent Clinical End
Point Committee.
CABG  coronary artery bypass graft surgery; MI  myocardial infarction;
PCI  percutaneous coronary intervention.
Figure 2 Continued.
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or stroke in 21 patients, noncardiac-related in 6, and
unknown in 10.
Myocardial infarctions. Most MIs in both groups oc-
curred in the first six months. During the first week, there
were more patients with MI in the invasive group than in
the noninvasive group. In contrast, after the first week, there
were more MIs in the noninvasive group than in the
invasive group (Table 2, Fig. 1B). Although the risk was
lower during the second half of the year, the relative benefit
of the invasive strategy also remained during this period.
Also during the second year, the event curves for MI
continued to diverge for the two treatment strategies.
Therefore, the absolute reduction in MIs at 12 months
(3.0%) had increased to 3.5% at 24-month follow-up. The
timing of MIs after the first year of follow-up is illustrated
in Figure 2.
Spontaneous and procedure-related MIs. During the
first six months, 241 events were classified as MIs by the
End Point Committee. In this period, two-thirds of the
MIs in the invasive group were considered “procedure-
related” (Table 3), most of them occurring after coronary
angioplasty. In contrast, four of five MIs in the noninvasive
group were considered as “spontaneous.” Thus, during the
first six months, procedure-related MIs were 2.5 times more
common in the invasive than in the noninvasive group (n 
66 [5.4%] vs. 26 [2.1%]; risk ratio 2.57 [95% CI 1.64 to
4.01]; p  0.001). In contrast, spontaneous MIs occurred
only in one-third as many patients in the invasive group (n
 33 [2.7%]) as in the noninvasive group (n  103 [8.5%];
risk ratio 0.32 [95% CI 0.22 to 0.48]; p  0.001). Most of
the procedure-related MIs occurred within the first months.
In the invasive group, 63 of the 68 MIs during the first
hospital period were procedure-related. When the
procedure-related MIs were related to PCI, the prognosis
was not different from that of PCI-treated patients without
procedure-related MIs. None of the patients with a PCI
procedure-related MI died during the whole follow-up
period, compared with 13 (1.8%) of 726 PCI-treated
patients without PCI-related MIs (p  NS). Five of the
patients (7.8%) with a PCI-related MI had a nonprocedure-
related MI during follow-up, compared with 55 (7.6%) of
PCI-treated patients without PCI-related MIs (p  NS).
The timing of the events is illustrated in Figure 3. In the
noninvasive group, 10 patients had procedure-related and
Figure 3. Timing of spontaneous myocardial infarctions (MIs) or death in percutaneous coronary intervention (PCI)-treated patients with (n  64,
continuous line) or without (n  726, broken line) PCI-related MIs.
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21 had spontaneous MIs during the first hospital period.
During the first six months after discharge, most MIs
occurred in the noninvasive cohort, and most of these were
spontaneous. Of the 95 patients in the noninvasive group
with MI after discharge but within six months, 14 had only
procedure-related MIs, 3 had both spontaneous and
procedure-related MIs, and 78 had only spontaneous MIs.
Only three patients in the invasive group had procedure-
related MI during this period.
Also in the period after six months, spontaneous MIs
occurred less often in the invasive group (n  18 [1.5%])
than in the noninvasive group (n  34 [2.8%]; risk ratio
0.53 [95% CI 0.30 to 0.93]; p  0.025). The event curves
of all spontaneous MIs are shown in Figure 4.
Death or MI. Most combined events (death/MI) occurred
during the first six months, with a concentration of proce-
dure related events in the first week in the invasive group
and spontaneous events during the first six months in the
noninvasive group (Table 4). The difference in event rates
between the two strategies continued to increase during the
two years of follow-up. At 12 months, the absolute reduc-
tion of death/MI was 3.7%, which increased to 4.2% at 24
months. These event curves continued to diverge during the
second year, although this further separation was not sta-
tistically significant (Fig. 2C). In the noninvasive group,
more patients without revascularizations during the first
year tended to have an event during the second year of
follow-up (n  26 [3.9%]), as compared with patients
revascularized during the first year (n  11 [2.1%]; p 
0.087).
Revascularizations. In the invasive group, 60.6% of the
patients were revascularized within the first week, 75.9%
during the first hospital period, and 78% at one year.
Between 12 and 24 months, no additional patients were
revascularized in this group, although a few patients needed
a repeat intervention during the second year (Table 5). In
the noninvasive group, most revascularizations were per-
formed after the first week but within the first six months.
In this group, the revascularization rates were 43% and 45%
at 12 and 24 months, respectively. Thus, in patients ran-
Figure 4. Probability of “spontaneous” myocardial infarction (MI) in the invasive (continuous broad line) and noninvasive (dotted narrow line) groups,
illustrated by Kaplan-Meier (1  survival) curves. See text for explanation. The p value was derived by the log-rank test between the two groups.
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domized to an early invasive strategy, 44% underwent PCI
and 38% had CABG during the 24 months, as compared
with 23% and 25%, respectively, in the noninvasive group.
After the first week, most revascularizations were per-
formed in the noninvasive strategy group (Table 5). These
unplanned and late revascularizations were the primary
intervention in most patients in this group. In the invasive
group, nearly all of these were repeat interventions. How-
ever, repeat interventions still were proportionally less com-
mon among the revascularized patients in the invasive than
in the noninvasive group. In the invasive group, a second
intervention was performed in 76 (14.3%) of the 530
patients primarily treated with angioplasty, as compared
with 56 (21.5%) of 260 patients in the noninvasive group
(risk ratio 0.67, 95% CI 0.49 to 0.91; p 0.011). In the 690
patients who had CABG as the first procedure, only 23 had
another revascularization during the follow-up period: 7
(1.6%) in the invasive group and 16 (6.0%) in the noninva-
sive group (risk ratio 0.27, 95% CI 0.11 to 0.65; p 0.002).
The mean time between the first and second intervention
did not differ between the two groups: 157  173) days and
136  172) days in the invasive group and noninvasive
group, respectively.
The timing of the events are illustrated in Figure 5, where
the patients are classified into groups according to the type
of their first revascularization. In the invasive group, there
was a significant difference in MIs between the different
revascularization types, with the highest rate in PCI-treated
patients. This difference could not be seen in spontaneous
MIs (Fig. 5C). The mortality was also low in the PCI-
treated patients in the invasive group (Fig. 5A).
Repeat hospital admissions. Repeat admissions to hospi-
tals were more common among patients randomized to a
noninvasive strategy (Table 6), both early after discharge
and later on during follow-up. Less than half of the repeat
admissions were registered as caused by angina pectoris.
Repeat admissions due to angina pectoris were less frequent
in the invasive group (n  209 [17.1%]) than in the
noninvasive group (n  348 [28.2%]; p  0.001; risk ratio
0.61, 95% CI 0.52 to 0.71) during the first 24 months.
During the second year, repeat admissions due to angina
pectoris were less frequent in the invasive group (n  54
[4.6%]) than in the noninvasive group (n  84 [7.1%]; risk
ratio 0.64, 95% CI 0.46 to 0.89).
DISCUSSION
The 24-month follow-up of the FRISC-II trial showed a
comforting sustained reduction and continuous divergence
in the event rates by use of an early invasive strategy in
patients with UCAD. Thus, the absolute difference in
events was larger at two years than at one-year follow-up.
There was a further increase in MIs in the invasive group,
with a continuous separation of the event curves of the two
strategies after the first year. The difference in mortality
observed at 12 months was sustained during the second
year. The total event rate was low after the first year, as only
2% of patients had MI in the noninvasive group and half
in the invasive group. However, during follow-up, almost
half of the patients in the noninvasive group had “crossed
over” and become revascularized, most of them during the
first year. In the noninvasive group, most of the events
Table 4. Death or Myocardial Infarction in Six-Month Periods in the Invasive and
Noninvasive Groups
n*
Invasive
Group
Noninvasive
Group
Risk
Ratio 95% CI p Value
First week† 1,222/1,235 67 (5.5%) 36 (2.9%) 1.88 1.26–2.80
Second week to 6 months 1,214/1,230 48 (4.0%) 118 (9.6%) 0.41 0.30–0.57
7 to 12 months 1,193/1,194 17 (1.4%) 28 (2.3%) 0.61 0.33–1.10
13 to 18 months 1,190/1,182 17 (1.4%) 20 (1.7%) 0.84 0.44–1.60
19 to 24 months 1,179/1,174 11 (0.9%) 18 (1.5%) 0.61 0.29–1.28
Total 0 to 24 months 1,210/1,227 146 (12.1%) 200 (16.3%) 0.74 0.61–0.90 0.003
*Figures show evaluated patients in the invasive/noninvasive groups. †The first six-month period is subdivided into the first week
and second week to six months.
CI  confidence interval.
Table 5. Revascularized Patients During Two Years in Six-Month Periods in the Invasive and
Noninvasive Groups
n*
Invasive
Group
Noninvasive
Group
Risk
Ratio 95% CI p Value
First week† 1,222/1,235 741 (60.6%) 58 (4.7%) 12.91 10.00–16.67
Second week to 6 months 1,213/1,223 261 (21.5%) 408 (33.4%) 0.65 0.56–0.74
7 to 12 months 1,192/1,193 21 (1.8%) 85 (7.1%) 0.25 0.15–0.40
13 to 18 months 1,185/1,180 8 (0.7%) 32 (2.7%) 0.25 0.12–0.54
19 to 24 months 1,171/1,169 5 (0.4%) 14 (1.2%) 0.36 0.13–0.99
Total 0 to 24 months 1,222/1,235 955 (78.2%) 561 (45.4%) 1.72 1.61–1.84  0.001
*Figures show evaluated patients in the invasive/noninvasive groups. †The first six-month period is subdivided into the first week
and second week to six months.
CI  confidence interval.
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Figure 5. Probability of death (A), myocardial infarction (B), and “spontaneous” myocardial infarction (C) in the invasive cohort with percutaneous coronary
intervention as the first invasive procedure (n  530, small dotted line at bottom), with coronary artery bypass graft surgery as the first invasive procedure
(n 425, thick short and long dotted line), and without any revascularization (n 267, continuous narrow line), and the noninvasive cohort (n 1,235,
broken narrow line), illustrated by Kaplan-Meier (1  survival) curves. The p value was derived by the log-rank test between the three different treatments
in the invasive cohort. Continued on next page.
during the second year occurred in patients who were not
revascularized during the first year. This “under-
revascularization” could probably explain the continuing
difference in the event rate during the second year.
The long-term results of this study demonstrate that an
early invasive strategy in combination with appropriate
preventive medical treatment rapidly transforms UCAD
into a stable condition, with a yearly rate of death or MI of
1% to 3%. In addition, other reports on angioplasty in
patients with UCAD have reported long-term outcomes
similar to those of patients with stable coronary disease,
even after 10 years of follow-up (9,10). This low event rate
is also in accordance with the low event rates in populations
with stable coronary heart disease (11). There was a pro-
portionally lower rate of repeat interventions after early
interventions, compared with when the procedures were
done later, as in the noninvasive group. The invasively
treated patients in the two randomized groups did not differ
with respect to the completeness of revascularization or
stent use (6). However, the revascularized patients in the
noninvasive group contained a higher proportion patients
with multivessel disease, which may, at least partly, explain
the higher “re-do” rate.
The present FRISC-II trial is still the only study that has
documented a decrease in mortality with an early invasive
strategy in patients with UCAD. In the TACTICS–
Table 6. Patients Re-Admitted to the Hospital During Two Years in Six-Month Periods in the
Invasive and Noninvasive Groups
n*
Invasive
Group
Noninvasive
Group
Risk
Ratio 95% CI p Value
First week† 1,222/1,235 12 (1.0%) 32 (2.6%) 0.38 0.20–0.73
Second week to 6 months 1,213/1,223 346 (28.5%) 574 (46.9%) 0.61 0.55–0.68
7 to 12 months 1,192/1,193 190 (15.9%) 256 (21.4%) 0.74 0.63–0.88
13 to 18 months 1,185/1,180 107 (9.0%) 160 (13.6%) 0.66 0.53–0.84
19 to 24 months 1,171/1,169 127 (10.8%) 159 (13.6%) 0.80 0.64–0.99
Total 0 to 24 months 1,222/1,235 547 (44.8%) 796 (64.5%) 0.69 0.64–0.75  0.001
*Figures show evaluated patients in the invasive/noninvasive groups. †The first six-month period is subdivided into the first week
and second week to six months.
CI  confidence interval.
Figure 5 Continued.
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TIMI-18 trial, the early invasive strategy was associated
with a reduction in the combined end point of death/MI/
repeat hospital admission. There was, however, no differ-
ence in death alone (8): 3.3% and 3.5%, respectively, in the
invasive and conservative groups at six months. The gain in
events in the TACTICS–TIMI-18 trial was mainly seen in
the first weeks, whereas in the FRISC-II trial there was,
after the first weeks, a continuous increase in benefit during
the two-year follow-up period. In the FRISC-II trial, there
appeared to be an early hazard, with a higher rate of MI in
the invasive group. The present analysis demonstrates that
this was entirely caused by procedure-related MIs, mainly
elevations of cardiac markers after angioplasty without any
other symptoms or signs of MI or any immediate clinical
consequences. This analysis also showed that this early
hazard after one month, and even more so after longer
follow-up, was compensated by a pronounced reduction in
spontaneous MIs. Furthermore, there were no indications
that the increased rate of procedure-related MIs was related
to any increased rate of late deaths or repeat MIs. Thus, the
negative impact on survival and repeat MI by small
procedure-related MIs is probably less than that by spon-
taneous MIs. The lower rate of early procedure-related MI
in the TACTICS–TIMI-18 trial might be mainly explained
by the fact that all patients were treated with a glycoprotein
IIb/IIIa inhibitor, which is known to halve the risk of
procedure-related MIs (12–14). In contrast, in the
FRISC-II trial, only 9% of angioplasty-treated patients in
the invasive group were treated with a glycoprotein IIb/IIIa
inhibitor. Therefore, it is likely that more frequent use of
glycoprotein IIb/IIIa inhibitors in the FRISC-II study
should had resulted in an even lower event rate in invasively
treated patients.
There are few other randomized studies of an invasive
versus noninvasive strategy in patients with UCAD. Studies
with longer follow-up periods are even rarer. The Veterans
Affairs study of unstable angina that started 25 years ago
(2) compared CABG with medical treatment. There was a
weak trend toward lower mortality in the surgical group in
the beginning, but this trend disappeared during the 10-year
follow-up period. In a subset of patients with poor left
ventricular function, there was initially lower mortality, but
this difference was not significant after 10 years (3). In the
VANQWISH trial, the patients were followed for an
average of 23 months (4). The initial advantage of the
conservative strategy disappeared during long-term
follow-up. After CABG, the 30-day mortality rate was very
high in the invasive group (11.6%) and in the conservative
group (3.4%); the corresponding mortality rates in
FRISC-II were 2.1% and 1.7%, respectively. Furthermore,
in the VANQWISH trial at one year, the revascularization
rate in the invasive arm was only 44%, fairly similar to that
in the noninvasive arm (33%), in contrast to 78% and 43%,
respectively, at the same time in the invasive and noninva-
sive groups of the FRISC-II trial. Thus, provided that the
early procedure-related hazards at CABG can be kept at a
low rate, an early invasive strategy will lead to improved
survival and a reduced risk of MI, as shown in the long-term
follow-up of the FRISC-II trial. Furthermore, the early
invasive strategy will also be associated with lower cardiac
morbidity and less consumption of health-care resources
later, as shown by the reductions in repeat admissions and
late revascularization procedures in this two-year follow-up
in the FRISC-II trial.
Study limitations. The independent End Point Commit-
tee only adjudicated events up to six months. Thereafter,
the presence of an event was collected by telephone con-
tact with the patients and evaluation of the medical
records by the local investigator. During the first six
months, minor elevations in myocardial markers were
routinely recorded in connection with angioplasty and
used as the basis for the diagnosis of MI, even without
any other symptoms or signs. Thereafter, the diagnosis of
MI, with or without angioplasty, was established by local
clinical routine. Therefore, the number of procedure-related
MIs in the noninvasive group might have been underesti-
mated.
Conclusions. In patients with UCAD, the early invasive
approach leads to a sustained reduction in mortality, cardiac
morbidity, and the need for repeat hospital admissions and
late revascularization procedures. The early increased risk of
procedure-related MIs is compensated for by a later reduc-
tion in spontaneous MIs. Although the benefits in the
invasive group are greatest during the first months, there is
still lower cardiac morbidity and less need for hospital care
during the second year.
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